Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group. [electronic resource]
Producer: 19990304Description: 155-60 p. digitalISSN:- 0887-6924
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Asparaginase -- adverse effects
- Child
- Child, Preschool
- Epirubicin -- adverse effects
- Escherichia coli -- enzymology
- Female
- Humans
- Infant
- Male
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Remission Induction -- methods
- Taiwan -- epidemiology
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.